Back to Search Start Over

Variants in the GPR146 Gene Are Associated With a Favorable Cardiometabolic Risk Profile.

Authors :
Rimbert A
Yeung MW
Dalila N
Thio CHL
Yu H
Loaiza N
Oldoni F
van der Graaf A
Wang S
Said MA
Blauw LL
Girardeau A
Bray L
Caillaud A
Bloks VW
Marrec M
Moulin P
Rensen PCN
van de Sluis B
Snieder H
Di Filippo M
van der Harst P
Tybjaerg-Hansen A
Zimmerman P
Cariou B
Kuivenhoven JA
Source :
Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2022 Oct; Vol. 42 (10), pp. 1262-1271. Date of Electronic Publication: 2022 Sep 01.
Publication Year :
2022

Abstract

Background: In mice, GPR146 (G-protein-coupled receptor 146) deficiency reduces plasma lipids and protects against atherosclerosis. Whether these findings translate to humans is unknown.<br />Methods: Common and rare genetic variants in the GPR146 gene locus were used as research instruments in the UK Biobank. The Lifelines, The Copenhagen-City Heart Study, and a cohort of individuals with familial hypobetalipoproteinemia were used to find and study rare GPR146 variants.<br />Results: In the UK Biobank, carriers of the common rs2362529-C allele present with lower low-density lipoprotein cholesterol, apo (apolipoprotein) B, high-density lipoprotein cholesterol, apoAI, CRP (C-reactive protein), and plasma liver enzymes compared with noncarriers. Carriers of the common rs1997243-G allele, associated with higher GPR146 expression, present with the exact opposite phenotype. The associations with plasma lipids of the above alleles are allele dose-dependent. Heterozygote carriers of a rare coding variant (p.Pro62Leu; n=2615), predicted to be damaging, show a stronger reductions in the above parameters compared with carriers of the common rs2362529-C allele. The p.Pro62Leu variant is furthermore shown to segregate with low low-density lipoprotein cholesterol in a family with familial hypobetalipoproteinemia. Compared with controls, carriers of the common rs2362529-C allele show a marginally reduced risk of coronary artery disease ( P =0.03) concomitant with a small effect size on low-density lipoprotein cholesterol (average decrease of 2.24 mg/dL in homozygotes) of this variant. Finally, mendelian randomization analyses suggest a causal relationship between GPR146 gene expression and plasma lipid and liver enzyme levels.<br />Conclusions: This study shows that carriers of new genetic GPR146 variants have a beneficial cardiometabolic risk profile, but it remains to be shown whether genetic or pharmaceutical inhibition of GPR146 protects against atherosclerosis in humans.

Details

Language :
English
ISSN :
1524-4636
Volume :
42
Issue :
10
Database :
MEDLINE
Journal :
Arteriosclerosis, thrombosis, and vascular biology
Publication Type :
Academic Journal
Accession number :
36047410
Full Text :
https://doi.org/10.1161/ATVBAHA.122.317514